Cargando…
A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL
Patients with diffuse large B-cell lymphoma (DLBCL) have a median age of 70 years. Yet, empirical knowledge about the treatment of older patients is limited because they are frequently excluded from clinical trials. We aimed to construct a simplified frailty score and examine survival and treatment-...
Autores principales: | Isaksen, Kathrine T., Mastroianni, Maria Adele, Rinde, Marit, Rusten, Leiv Sindre, Barzenje, Dlawer Abdulla, Ramslien, Lloyd Frode, Slaaen, Marit, Jerm, Marianne Brenn, Smeland, Erlend B., Rostoft, Siri, Liestøl, Knut, Brodtkorb, Marianne, Holte, Harald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759139/ https://www.ncbi.nlm.nih.gov/pubmed/34543384 http://dx.doi.org/10.1182/bloodadvances.2021004777 |
Ejemplares similares
-
The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
por: Isaksen, Kathrine T., et al.
Publicado: (2023) -
The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
por: Manfroi, Benoît, et al.
Publicado: (2021) -
A germinal center–associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL
por: Miyawaki, Kohta, et al.
Publicado: (2022) -
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022) -
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
por: Mazzara, Saveria, et al.
Publicado: (2022)